ESMC_2012.12.31-10Q 2013

 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
 

 FORM 10-Q
QUARTERLY PERIOD PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 
 

For the Quarterly Period ended December 31, 2012
Commission File Number 0-20127

 
 

Escalon Medical Corp.
(Exact name of registrant as specified in its charter)

 
 

Pennsylvania
 
33-0272839
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
435 Devon Park Drive, Building 100, Wayne, PA 19087
(Address of principal executive offices, including zip code)
(610) 688-6830
(Registrant’s telephone number, including area code)

 
 

N/A
Former name, former address and former fiscal year, if changed since last report
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

 


Large accelerated filer
 
o
 
Accelerated filer
 
o
 
 
 
 
 
 
Non-accelerated filer
 
o (Do not check if a smaller reporting company)
 
Smaller reporting company
 
x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  o    No  x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 7,526,430 shares of common stock, $0.001 par value, outstanding as of February 13, 2013.




 
TABLE OF CONTENTS
 
 
Page
 

Item I.
 


 

 
 
Item 2.
Item 3.
Item 4T.
 
 
 
 

Item 1.
Item 1A.
Item 6.
 


1


Item 1. Condensed Consolidated Financial Statements
ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
 
December 31,
2012
 
June 30,
2012
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
3,578,230

 
$
890,623

Accounts receivable, net
1,822,467

 
1,343,823

Inventory, net
1,712,352

 
1,434,260

Other current assets
173,549

 
199,312

Assets of discontinued operations
—

 
4,012,725

Total current assets
7,286,598

 
7,880,743

Property and equipment, net
12,831

 
12,954

Goodwill
125,027

 
125,027

Trademarks and trade names
605,006

 
605,006

Patents, net
7,983

 
14,852

Non-current assets of discontinued operations
—

 
1,111,883

Total assets
$
8,037,445

 
$
9,750,465

LIABILITIES AND SHAREHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Related party note payable
—

 
300,000

Accounts payable
992,911

 
660,274

Accrued expenses
918,043

 
1,335,744

Current portion of long-term debt, discontinued operations
$
—

 
$
4,149,516

Liabilities of discontinued operations
338,145

 
1,617,814

Total current liabilities
2,249,099

 
8,063,348

Accrued post-retirement benefits
1,042,252

 
1,042,252

Total long-term liabilities
1,042,252

 
1,042,252

Total liabilities
3,291,351

 
9,105,600

Shareholders equity:
 
 
 
Preferred stock, $0.001 par value; 2,000,000 shares authorized; no shares issued
—

 
—

Common stock, $0.001 par value; 35,000,000 shares authorized; 7,526,430 issued and outstanding
7,526

 
7,526

Common stock warrants
132,114

 
132,114

Additional paid-in capital
69,395,305

 
69,369,658

Accumulated deficit
(64,788,851
)
 
(68,348,811
)
Accumulated other comprehensive loss
—

 
(515,622
)
Total shareholders’ equity
4,746,094

 
644,865

Total liabilities and shareholders’ equity
$
8,037,445

 
$
9,750,465

See notes to condensed consolidated financial statements

2

ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

 
Three Months Ended December 31,
Six Months Ended December 31,
 
2012
 
2011
2012
 
2011
Net revenues:
 
 
 
 
 
 
Product revenue
$
3,640,761

 
$
3,185,932

$
5,910,338

 
$
5,592,512

Revenues, net
3,640,761

 
3,185,932

5,910,338

 
5,592,512

Costs and expenses:
 
 
 
 
 
 
Cost of goods sold
1,776,054

 
1,461,898

2,972,452

 
2,686,326

Marketing, general and administrative
1,488,915

 
1,534,735

2,894,501

 
2,914,262

Research and development
266,169

 
210,527

530,367

 
430,077

Total costs and expenses
3,531,138

 
3,207,160

6,397,320

 
6,030,665

Income (loss) from operations
109,623

 
(21,228
)
(486,982
)
 
(438,153
)
Other (expense) income
 
 
 
 
 
 
Other income
16,842

 
446

81,623

 
1,144

Interest income
62

 
44

91

 
82

Interest expense
—

 
(88,059
)
(92,596
)
 
(170,550
)
Total other (expense) income
16,904

 
(87,569
)
(10,882
)
 
(169,324
)
Net income (loss) from continuing operations
126,527

 
(108,797
)
(497,864
)
 
(607,477
)
Net income (loss) from discontinued operations before tax
3,946,858

 
(3,426,203
)
4,137,824

 
(3,717,172
)
Income tax expense
(80,000
)
 
—

(80,000
)
 
—

Net income (loss) from discontinued operations, net of tax
3,866,858

 
(3,426,203
)
4,057,824

 
(3,717,172
)
Net income (loss)
$
3,993,385

 
$
(3,535,000
)
$
3,559,960

 
$
(4,324,649
)
Net income (loss) per share
 
 
 
 
 
 
Basic:
 
 
 
 
 
 
Continuing operations
$
0.02

 
$
(0.01
)
$
(0.07
)
 
$
(0.08
)
Discontinued operations
0.51

 
(0.46
)
0.54

 
(0.50
)
Net income (loss)
$
0.53

 
$
(0.47
)
$
0.47

 
$
(0.58
)
Diluted:
 
 
 
 
 
 
Continuing operations
$
0.02

 
$
(0.01
)
$
(0.07
)
 
$
(0.08
)
Discontinued operations
0.51

 
(0.46
)
0.54

 
(0.50
)
Net income (loss)
$
0.53

 
$
(0.47
)
$
0.47

 
$
(0.58
)
Weighted average shares—basic
7,526,430

 
7,526,430

7,526,430

 
7,526,430

Weighted average shares—diluted
7,526,430

 
7,526,430

7,526,430

 
7,526,430

See notes to condensed consolidated financial statements

3

ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS )
(UNAUDITED)


Three months ended December 31,
 
Six months ended December 31,


2012
 
2011
 
2012
 
2011
Net income (loss)
$
3,993,385

 
$
(3,535,000
)
 
$
3,559,960

 
$
(4,324,649
)
Foreign currency translation
(971
)
 
303,643

 
(62,800
)
 
401,418

Add: reclassification adjustment for foreign currency losses included in net income (loss)
578,422

 
—

 
578,422

 
—

  Total comprehensive income (loss)
$
4,570,836

 
$
(3,231,357
)
 
$
4,075,582

 
$
(3,923,231
)
 
 
 
 
 
 
 
 
See notes to condensed consolidated financial statements


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY
FOR THE SIX MONTHS ENDED DECEMBER 31, 2012
(UNAUDITED)

 
Common Stock
 
Common
Stock
Warrants
 
Additional
Paid-in
Capital
 
Accumulated
Deficit
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Total Shareholders' Equity
 
Shares
 
Amount
 
  
 
 
 
 
 
 
 
 
Balance at June 30, 2012
7,526,430

 
$
7,526

 
$
132,114

 
$
69,369,658

 
$
(68,348,811
)
 
$
(515,622
)
 
$
644,865

Net income
—

 
—

 
—

 
—

 
3,559,960

 
—

 
3,559,960

Other comprehensive income
—

 
—

 
—

 
—

 
—

 
515,622

 
515,622

Compensation expense
—

 
—

 
—

 
25,647

 
—

 
—

 
25,647

Balance at December 31, 2012
7,526,430

 
$
7,526

 
$
132,114

 
$
69,395,305

 
$
(64,788,851
)
 
$
—

 
$
4,746,094

See notes to condensed consolidated financial statements

4

ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 
For the six months ended December 31,
 
2012
 
2011
Cash Flows from Operating Activities:
 
 
 
Net income (loss)
$
3,559,960

 
$
(4,324,649
)
Adjustments to reconcile net income (loss) to cash provided by operating activities of continuing operations:
 
 
 
(Income) loss from discontinued operations
(4,057,824
)
 
3,717,172

Depreciation and amortization
6,992

 
3,707

Compensation expense related to stock options
25,647

 
40,383

Other income
(81,623
)
 
(1,144
)
Change in operating assets and liabilities:
 
 
 
Accounts receivable, net
(478,644
)
 
445,650

Inventory, net
(278,092
)
 
(353,301
)
Other current and long term-assets
25,763

 
(20,824
)
Accounts payable and accrued expenses
173,081

 
227,404

Net cash (used in) operating activities from continuing operations
(1,104,740
)
 
(265,602
)
Net cash provided by (used in) operating activities from discontinued operations
88,445

 
(457,771
)
Net cash (used in) operating activities
(1,016,295
)
 
(723,373
)
Cash Flows from Investing Activities:
 
 
 
 
 
 
 
Purchase of fixed assets
—

 
(13,125
)
Net cash (used in) investing activities from continuing operations
—

 
(13,125
)
Proceeds from sale of Drew Scientific
6,500,000

 
—

Purchase of fixed assets, discontinued operations
(8,618
)
 
(41,605
)
Net cash provided by (used in) investing activities from discontinued operations
6,491,382

 
(41,605
)
Net cash provided by (used in) investing activities
6,491,382

 
(54,730
)
Cash Flows from Financing Activities:
 
 
 
Proceeds from (repayments of) related party note payable
(300,000
)
 
300,000

Net cash used in (provided by) financing activities from continuing operations
(300,000
)
 
300,000

Principal payments on long-term debt
(2,487,480
)
 
(155,795
)
Net cash used in financing activities from discontinued operations
(2,487,480
)
 
(155,795
)
Net cash (used in) provided by financing activities
(2,787,480
)
 
144,205

Effect of exchange rate changes on cash and cash equivalents
—

 
50,225

Net increase (decrease) in cash and cash equivalents
2,687,607

 
(583,673
)
Cash and cash equivalents, beginning of period
890,623

 
1,684,746

Cash and cash equivalents, end of period
$
3,578,230

 
$
1,101,073

Supplemental Schedule of Cash Flow Information:
 
 
 
 
 
 
 
             Interest paid
$
32,216

 
$
163,599

See notes to condensed consolidated financial statements

5

Escalon Medical Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(UNAUDITED)

1. Basis of Presentation

 Escalon Medical Corp. (“Escalon” or the “Company” ) is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Trek, Inc. (“Trek”), Escalon Medical Europe GmbH (“EME”), Escalon Digital Vision, Inc. (“EMI”), Escalon Pharmaceutical, Inc. (“Pharmaceutical”), Escalon Holdings, Inc. (“EHI”), Escalon IP Holdings, Inc., Sonomed IP Holdings, Inc., Drew Scientific Holdings (discontinued), Inc., Drew Scientific Inc. (discontinued), and Drew Scientific Group, Plc (“Drew”) and its subsidiaries (discontinued). All intercompany accounts and transactions have been eliminated.

On October 3, 2012 the Company sold its Clinical Diagnostics Business to ERBA Diagnostics, Inc. The Escalon Clinical Diagnostics Business ("ECD") consists of Drew Scientific, Inc., and its wholly owned subsidiaries JAS Diagnostics, Inc. ("JAS") and Drew Scientific Limited Co. The sales price was $6,500,000 in cash. The sale of this business will have a material effect on earnings in subsequent periods. ECD prior period amounts are presented as discontinued operations (see footnote 10 to the Notes to Condensed Consolidated Financial Statements for additional information).

On October 18, 2012, the Company and its debt holder reached an agreement whereby the Company paid the balance of the seller-provided financing plus accrued interest related to the purchase of certain assets of BH Holdings, S.A.S ("Biocode" or "BHH") of $4,367,604 with a one-time payment of $2,487,480 resulting in a gain on extinguishment of debt of $1,880,124 which was included in discontinued operations. The repayment of the debt has reduced the Company's debt related to Biocode to zero.

As a result of these transactions the Company realized total gains of $4,019,000 during the three-month period ending December 31, 2012. The total gain brought the Company back into compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing on the NASDAQ Capital Market as set forth in Listing Rule 5550(b).
    
The Company operates in the healthcare market, specializing in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other governmental authorities require extensive testing of new products prior to sale and have jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.

Management reviews financial information, allocates resources, and manages the business as two segments: Sonomed-Escalon and Escalon Medical Corp. (“Corporate”). The Sonomed-Escalon segment consists of Sonomed, Inc., EMI and Trek, all of which are engaged in the development and sale of Ophthalmic medical devices. The Escalon Medical Corp. segment includes the administrative corporate operations of the consolidated group.

2.               Stock-Based Compensation

Valuations are based upon highly subjective assumptions about the future, including stock price volatility and exercise patterns. The fair value of share-based payment awards was estimated using the Black-Scholes option pricing model. Expected volatilities are based on the historical volatility of the Company's stock. The Company uses historical data to estimate option exercise and employee terminations. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant.

The Company has historically granted options under the Company's option plans with an option exercise price equal to the closing market value of the stock on the date of the grant and with vesting, primarily for Company employees, either in equal annual amounts over a two- to five-year period or immediately, and, primarily for non-employee directors, immediately.

As of December 31, 2012 and 2011 total unrecognized compensation cost related to non-vested share-based compensation arrangements granted to employees under the 2004 Equity Incentive Plan was $29,110 and $87,726, respectively. The remaining cost is expected to be recognized over a weighted average period of 1.15 years. For the three-month periods ended December 31, 2012 and 2011, $9,162 and $16,484 was recorded as compensation expense, respectively. For the six-month periods ended December 31, 2012 and 2011, $25,647 and $40,383 was recorded as compensation expense, respectively.
 

6

The Company did not receive any cash from share option exercises under stock-based payment plans for the three month and six month periods ended December 31, 2012 and 2011. The Company did not realize any tax effect, which would be a reduction in its tax rate, on options due to the full valuation allowances established on its deferred tax assets.

The Company measures compensation expense for non-employee stock-based compensation based on the fair value of the options issued, as this is more reliable than the fair value of the services received. Fair value is measured as the value of the Company's common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty's performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. There was no non-employee compensation expense for the three-month and six-month periods ended December 31, 2012 and 2011.

3. Net Income (Loss) earnings per Share

The following table sets forth the computation of basic and diluted net income (loss) per share:
 
Three Months Ended December 31,
 
Six Months Ended December 31,
 
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
Numerator:
 
 
 
 
 
 
 
  Numerator for basic and diluted earnings per share
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
126,527

 
$
(108,797
)
 
$
(497,864
)
 
$
(607,477
)
Income (loss) from discontinued operations
3,866,858

 
(3,426,203
)
 
4,057,824

 
(3,717,172
)
 Net income (loss)
$
3,993,385

 
$
(3,535,000
)
 
$
3,559,960

 
$
(4,324,649
)
Denominator:
 
 
 
 
 
 
 
  Denominator for basic earnings per share - weighted average shares
7,526,430

 
7,526,430

 
7,526,430

 
7,526,430

  Effect of dilutive securities:
 
 
 
 
 
 
 
    Stock options and warrants
—

 
—

 
—

 
—

    Shares reserved for future exchange
—

 
—

 
—

 
—

 Denominator for diluted earnings per share - weighted average and assumed conversion

7,526,430

 
7,526,430

 
7,526,430

 
7,526,430

 
 
 
 
 
 
 
 
Net income (loss) per share
 
 
 
 
 
 
 
   Basic:
 
 
 
 
 
 
 
      Continuing operations
$
0.02

 
$
(0.01
)
 
$
(0.07
)
 
$
(0.08
)
      Discontinued operations
0.51

 
(0.46
)
 
0.54

 
(0.50
)
 
$
0.53

 
$
(0.47
)
 
$
0.47

 
$
(0.58
)
   Diluted:
 
 
 
 
 
 
 
      Continuing operations
$
0.02

 
$
(0.01
)
 
$
(0.07
)
 
$
(0.08
)
      Discontinued operations
0.51

 
(0.46
)
 
0.54

 
(0.50
)
 
$
0.53

 
$
(0.47
)
 
$
0.47

 
$
(0.58
)
     




7

All the outstanding warrants and options were excluded from the calculation of diluted earnings per share as the exercise price of the warrants and options exceeded the average share price of the company's common stock making the warrants and options anti-dilutive.

4. Legal Proceedings

The Company, from time to time is involved in various legal proceedings and disputes that arise in the normal course of business. These matters have previously and may in the future pertain to intellectual property disputes, commercial contract disputes, employment disputes, and other matters. The Company does not believe that the resolution of any of these matters has had or is likely to have a material adverse impact on the Company's business, financial condition or results of operations.

5. Segment Reporting
        
During the three-month and six-month periods ended December 31, 2012 and 2011, the Company's continuing operations were classified into two principal reportable business units that provide different products or services.
 
Management reviews financial information, allocates resources, and manages the business as two segments: Sonomed-Escalon and Escalon Medical Corp. (“Corporate”). The Sonomed-Escalon segment consists of Sonomed, Inc., EMI and Trek, all of which are engaged in the development and sale of ophthalmic medical devices. The Corporate segment includes the administrative corporate operations of the consolidated group. The ECD segment which consists of Drew Scientific, Inc., and its wholly owned subsidiary JAS, was reported under discontinued operations beginning with the Form 10-Q for three months ended September 30, 2012 and prior period segment information has been reclassified to conform with the current year presentation.

Separate management of each unit is required because each business unit is subject to different marketing, production and technology strategies.
The table below sets forth the income (loss) from continuing operations for the three months ended December 31, 2012 and 2011(in thousands).
 
 
Sonomed-Escalon
 
Corporate
 
Total
 
 
2012
 
2011
 
2012
 
2011
 
2012
 
2011
Revenues, net:
 
 
 
 
 
 
 
 
 
 
 
 
Product revenue
 
$
3,641

 
$
3,186

 
$
—

 
$
—

 
$
3,641

 
$
3,186

Total revenue, net
 
3,641

 
3,186

 
—

 
—

 
3,641

 
3,186

Costs and expenses:
 
 
 
 
 
 
 
 
 
 
 
 
Cost of goods sold
 
1,776

 
1,462

 
—

 
—

 
1,776

 
1,462

Marketing, general & administration
 
1,340

 
1,402

 
149

 
133

 
1,489

 
1,535

Research & development
 
266

 
211

 
—

 
—

 
266

 
211

Total costs and expenses
 
3,382

 
3,075

 
149

 
133

 
3,531

 
3,208

Income (loss) income from operations
 
259

 
111

 
(149
)
 
(133
)
 
110

 
(22
)
Other (expense) and income:
 
 
 
 
 
 
 
 
 
 
 
 
Other income (expense)
 
—

 
—

 
17

 
—

 
17

 
—

Interest expense
 
—

 
—

 
—

 
(88
)
 
—

 
(88
)
Total other (expense) and income
 
—

 
—

 
17

 
(88
)
 
17

 
(88
)
Income (loss) before taxes
 
259

 
111

 
(132
)
 
(221
)
 
127

 
(110
)
Income taxes (benefits) from continuing operations
 
—

 
—

 
—

 
—

 
—

 
—

Net income (loss) from continuing operations
 
$
259

 
$
111

 
$
(132
)
 
$
(221
)
 
$
127

 
$
(110
)
    
 The table below sets forth the loss from continuing operations for the six months ended December 31, 2012 and 2011(in thousands).

8

 
 
Sonomed-Escalon
 
Corporate
 
Total
 
 
2012
 
2011
 
2012
 
2011
 
2012
 
2011
Revenues, net:
 
 
 
 
 
 
 
 
 
 
 
 
Product revenue
 
$
5,910

 
$
5,593

 
$
—

 
$
—

 
$
5,910

 
$
5,593

Total revenue, net
 
5,910

 
5,593

 
—

 
—

 
5,910

 
5,593

Costs and expenses:
 
 
 
 
 
 
 
 
 
 
 
 
Cost of goods sold
 
2,972

 
2,686

 
—

 
—

 
2,972

 
2,686

Marketing, general & admin
 
2,683

 
2,689

 
212

 
226

 
2,895

 
2,915

Research & development
 
530

 
430

 
—

 
—

 
530

 
430

Total costs and expenses
 
6,185

 
5,805

 
212

 
226

 
6,397

 
6,031

(Loss) from operations
 
(275
)
 
(212
)
 
(212
)
 
(226
)
 
(487
)
 
(438
)
Other (expense) and income:
 
 
 
 
 
 
 
 
 
 
 
 
Other income
 
—

 
—

 
82

 
1

 
82

 
1

Interest expense
 
—

 
—

 
(93
)
 
(170
)
 
(93
)
 
(170
)
Total other (expense) and income
 
—

 
—

 
(11
)
 
(169
)
 
(11
)
 
(169
)
(Loss) before taxes
 
(275
)
 
(212
)
 
(223
)
 
(395
)
 
(498
)
 
(607
)
Income taxes (benefits) from continuing operations
 
—

 
—

 
—

 
—

 
—

 
—

Net (loss) from continuing operations
 
$
(275
)
 
$
(212
)
 
$
(223
)
 
$
(395
)
 
$
(498
)
 
$
(607
)


The Company operates in the healthcare market, specializing in the development, manufacture and marketing of ophthalmic medical devices and pharmaceuticals. The business segments reported above are the segments for which separate financial information is available and for which operating results are evaluated regularly by executive management in deciding how to allocate resources and assessing performance. The accounting policies of the business segments are the same as those described in the summary of significant accounting policies in the Company's Form 10-K for the year ended June 30, 2012. For the purposes of this illustration, corporate expenses, which consist primarily of executive management and administrative support functions, are allocated across the business segments based upon a methodology that has been established by the Company, which includes a number of factors and estimates and that has been consistently applied across the business segments. These expenses are otherwise included in the corporate segment.

During the three-month and six-month periods ended December 31, 2012 and 2011, Sonomed-Escalon derived its revenue from the sale of A-Scans, B-Scans, pachymeters, Digital imaging products, ISPAN™ gas products and various disposable ophthalmic surgical products.


6. Related Party Transactions
Escalon and a member of the Company’s Board of Directors are founding and equal members of Ocular Telehealth Management, LLC (“OTM”). OTM is a diagnostic telemedicine company providing remote examination, diagnosis and management of disorders affecting the human eye. OTM’s initial solution focuses on the diagnosis of diabetic retinopathy by creating access and providing annual dilated retinal examinations for the diabetic population. OTM was founded to harness the latest advances in telecommunications, software and digital imaging in order to create greater access and a more successful disease management for populations that are susceptible to ocular disease. Through December 31, 2012, Escalon had invested $444,000 in OTM and owned 45% of OTM. No additional investments were made during the six months ended December 31, 2012. The Company provides administrative support functions to OTM. For the three-month periods ended December 31, 2012 and 2011 the Company recorded a gain of $4,000 and $0, respectively. For the six-month periods ended December 31, 2012 and 2011 the Company recorded a gain of $5,000 and $1,000, respectively. At December 31, 2012 OTM had total assets, liabilities and equity of $22,000, $80,000 and ($58,000), respectively.
During the six-month period ended December 31, 2012, Richard J. DePiano, Sr., the Company’s Chief Executive Officer, participated in an accounts receivable factoring program that was implemented by the Company. Under the program, Mr. DePiano advanced the Company $300,000 which represented 80% of an amount due from certain Drew customers. The receivables were not eligible to be sold to the Company’s usual factoring agent. Interest on the transaction is 1.25% per month, which was equal to the best price offered by the Company’s usual factoring agent. The transaction excluded fees typically charged by the factoring

9

agent and provided much needed liquidity to the Company. Related party interest expense for the three-month periods ended December 31, 2012 and 2011 was $0 and $6,011, respectively. Related party interest expense for the six-month periods ended December 31, 2012 and 2011 was $11,250 and $9,773, respectively. The entire amount due of $332,216 including accrued interest of $32,216, was paid in full on October 5, 2012.

7.     Recently Issued Accounting Standards

In May 2011, the FASB issued ASU No. 2011-04 which provides a consistent definition of fair value in GAAP and International Financial Reporting Standards and ensures that their respective fair value measurement and disclosure requirements are the same (except for minor differences in wording and style). The amendments change certain fair value measurement principles and enhance the disclosure requirements particularly for level 3 fair value measurements. The standard became effective for the Company the current fiscal year and should be applied prospectively. The adoption of this ASU did not have a material impact on the Company's condensed consolidated financial statements.

In June 2011, the FASB issued ASU No. 2011-05 which requires an entity to present all non-owner changes in stockholders' equity either in a single continuous statement of comprehensive income or in two separate but consecutive statements. ASU 2011-05 eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. This standard became effective for the Company in the current fiscal year and should be applied retrospectively. The adoption of this ASU did not have a material impact on the Company's condensed consolidated financial statements.

In September 2011, the FASB issued ASU No. 2011-08, Intangibles-Goodwill and Other (Topic 350): Testing Goodwill for Impairment, which simplifies how an entity tests goodwill for impairment. Under that option, an entity no longer would be required to calculate the fair value of a reporting unit unless the entity determines, based on that qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The amendments became effective for the company for goodwill impairment tests performed during the current fiscal year and should be applied prospectively. The adoption of this ASU did not have a material impact on the Company's condensed consolidated financial statements.

8. Fair Value Measurements
On July 1, 2008, the Company adopted the FASB-issued authoritative guidance for the fair value of financial assets and liabilities. This standard defines fair value and establishes a hierarchy for reporting the reliability of input measurements used to assess fair value for all assets and liabilities. The FASB issued authoritative guidance defines fair value as the selling price that would be received for an asset, or paid to transfer a liability, in the principal or most advantageous market on the measurement date. The hierarchy established prioritizes fair value measurements based on the types of inputs used in the valuation technique. The inputs are categorized into the following levels:
Level 1—Observable inputs such as quoted prices in active markets for identical assets or liabilities.
Level 2—Directly or indirectly observable inputs for quoted and other than quoted prices for identical or similar assets and liabilities in active or non-active markets.
Level 3—Unobservable inputs not corroborated by market data, therefore requiring the entity to use the best available information available in the circumstances, including the entity’s own data.
Certain financial instruments are carried at cost on the consolidated balance sheets, which approximates fair value due to their short-term, highly liquid nature. These instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and related party note payable. The Company analyzed the fair value of the outstanding debt based on the remaining maturity of the note for the Biocode debt and other Level 3 measurements. By “other level 3 measurements” the Company is referring to “unobservable inputs not corroborated by market data, therefore requiring the entity to use the best available information available in the circumstances, including the entity’s own data”. The Company included this reference because in determining the estimated fair value of our debt we first attempted to use a “commonly accepted valuation methodology” of applying rates currently available to the Company for debt with similar terms and remaining maturities. The debt on the Company’s prior year balance sheet is related to the acquisition of Biocode Hycell on December 31, 2008. The acquisition was 100% financed by the seller. Management concluded that given the financial state of the Company and the overall state of the credit markets there is no financial institution that would make available funds to the Company for the 100% financing of a foreign entity with similar terms and remaining maturities, or in fact, on any terms. The Company then considered whether there was any “level 3” considerations, as defined above, which might aid the Company in determining the fair market value of this unique form of debt. The Company determined that there was not and came to the conclusion that given the weakened state of the Company and overall market conditions there was no other source of financing available to the Company, from any source on any terms, other than the willing seller of the Biocode assets.

10

On October 18, 2012, the Company and its debt holder reached an agreement whereby the Company paid the balance of the seller-provided financing plus accrued interest related to the purchase of certain assets of Biocode of $4,367,604 with a one-time payment of $2,487,480 resulting in a gain on extinguishment of debt of $1,880,124. The repayment of the debt has reduced the Company's debt to zero. The gain on the extinguishment of debt was recognized in the three-month period ended December 31, 2012. Based on this information it appears that the fair market value of the outstanding debt was less than the book value.

9. Continuing Operations

The accompanying condensed consolidated financial statements have been prepared on the going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

Based on the following transactions, the Company expects that these transactions will provide the Company with sufficient cash to fund its operations over the next 12 months.

On October 3, 2012 the Company sold its Clinical Diagnostics Business to ERBA Diagnostics, Inc. The ECD consisted of Drew Scientific, Inc., and its wholly owned subsidiaries JAS and Drew Scientific Limited Co. The sales price was $6,500,000 in cash and the transaction generated a gain on sale of approximately $2,717,000.

On October 18, 2012, the Company and its debt holder reached an agreement whereby the Company paid the balance of the seller-provided financing plus accrued interest related to the purchase of certain assets of Biocode of $4,367,604 with a one-time payment of $2,487,480 resulting in a gain on extinguishment of debt of $1,880,124. The repayment of the debt has reduced the Company's debt related to Biocode to zero.

As a result of these transactions the Company realized total gains of $4,019,000 before tax during the three-month period ended December 31, 2012 including $(578,422) of cumulative translation adjustment reversal related to the ECD segment. The total gain brought the Company back into compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing on the NASDAQ Capital Market as set forth in Listing Rule 5550(b).

On June 29, 2012, the Company received a letter from the NASDAQ Listing Qualifications Staff indicating that the Company is not in compliance with the $1.00 minimum closing bid price requirement under the NASDAQ Listing Rules (the "Listing Rules"). The Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share. If a NASDAQ-listed company trades below the minimum bid price requirement for 30 consecutive business days, it is notified of the deficiency. Based upon the Staff's review, the Company no longer meets this requirement. The Listing Rules provide the Company with a compliance period of 180 calendar days, or until December 26, 2012 in which to regain compliance with this requirement. The Company was not in compliance at the end of the 180-day compliance period and sought and received a hearing with the NASDAQ Staff to discuss its plan to reach compliance. The meeting was scheduled to take place on March 5, 2013. On January 17, 2013, the Company was advised by NASDAQ that the bid price deficiency of the Company was cured, and that the Company is currently in compliance with all applicable listing standards.


10. Discontinued Operations

BH Holdings, S.A.S

On January 12, 2012 BHH initiated the filing of an insolvency declaration with the Tribunal de Commerce de Rennes, France ("Commercial Court").  The Commercial Court on January 18, 2012 opened the liquidation proceedings with continuation of BHH's activity for 3 months and named an administrator to manage BHH. Since Drew no longer had a controlling financial interest in BHH it was deconsolidated in the December 31, 2011 quarterly condensed consolidated financial statements and prior period amounts were presented as discontinued operations.
The following tables summarize the results of discontinued operations of BHH for the three months and six months ended December 31, 2012 and 2011 (in thousands):

11

For the Three Months Ended December 31,
2012
 
2011
Revenue, net
$
—

 
$
970

Cost of goods sold
—

 
167

Marketing, general and administrative
—

 
1,050

Research & development
—

 
—

Total Costs and expenses
—

 
1,217

Loss from discontinued operations
—

 
(247
)
Loss on liquidation of net assets from discontinued operations
—

 
(2,216
)
Net loss from discontinued operations
$
—

 
$
(2,463
)

For the Six Months Ended December 31,
2012
 
2011
Revenue, net
$
—

 
$
1,970

Cost of goods sold
—

 
574

Marketing, general and administrative
—

 
1,945

Research & development
—

 
—

Total Costs and expenses
—

 
2,519

 
 
 
 
Loss from discontinued operations
—

 
(549
)
Loss on liquidation of net assets from discontinued operations
—

 
(2,216
)
Net loss from discontinued operations
$
—

 
$
(2,765
)


Assets and liabilities of discontinued operations of BHH included in the condensed consolidated balance sheets are summarized as follows at December 31, 2012 and June 30, 2012 (in thousands):
 
December 31,
 
June 30,

2012
 
2012
Assets
 
 
 
Total assets
$
—

 
$
—

Liabilities
 
 
 
Accounts payable
—

 
—

Accrued expenses
—

 
—

Accrued lease termination costs
338

 
338

Total liabilities
338

 
338

Net assets of discontinued operations
$
(338
)
 
$
(338
)
Discontinued operation of ECD
On October 3, 2012 the Company sold its Clinical Diagnostics Business to ERBA Diagnostics, Inc. The ECD consisted of Drew Scientific, Inc., and its wholly owned subsidiaries JAS and Drew Scientific Limited Co. The sales price was $6,500,000 in cash and gain on sales of assets was approximately $2,717,000.

12

 
October 3, 2012
Sales Price
$
6,500,000

Broker's fee
(325,000
)
Net Proceeds
6,175,000

Net Assets Sold
(3,457,931
)
Gain on Sale of Assets
$
2,717,069

 
 
Net assets sold
 
Assets:
 
  Cash and cash equivalents
$
4,378

  Accounts receivable, net
1,660,992

  Inventory, net
1,996,775

  Other current assets
112,980

Furniture and equipment, net
286,823

Goodwill
93,181

Trademarks and trade names, net
89,000

Customer list, net
461,558

Total Assets
4,705,687




Liabilities:
 
Accounts payable
638,541

Accrued expenses
609,215

Total liabilities
1,247,756

Net assets sold
$
3,457,931


On October 18, 2012, the Company and its debt holder reached an agreement whereby the Company paid the balance of the seller-provided financing plus accrued interest related to the purchase of certain assets of Biocode of $4,367,604 with a one-time payment of $2,487,480 resulting in a gain on extinguishment of debt of $1,880,124. The repayment of the debt has reduced the Company's debt related to Biocode to zero. The total gain from the extinguishment of debt and the gain on the sale of assets, offset by the cumulative translation adjustment ("CTA") related to Drew of $578,422 was $4,019,000 before tax.
The following table summarizes the results of discontinued operations for the three-months and six-months ended December 31, 2012 and 2011 (in thousands):
 
For the three months ended December 31,
2012
 
2011
Revenue, net
$
—

 
$
3,093

Cost of goods sold
—

 
2,822

Marketing, general and administrative
72

 
1,037

Research & development
—

 
110

Total costs and expenses
72

 
3,969

Other expense
—

 
(87
)
Net (loss) from discontinued operations
(72
)
 
(963
)
Gain from sale of assets and debt settlement net of tax (CTA included)
3,939

 
—

Net income (loss) from discontinued operations, net of tax
$
3,867

 
$
(963
)


13

For the six months ended December 31,
2012
 
2011
Revenue, net
$
3,637

 
$
6,707

Cost of goods sold
2,194

 
5,166

Marketing, general and administrative
1,248

 
2,133

Research & development
76

 
272

Total costs and expenses
3,518

 
7,571

Other expense
—

 
(88
)
Income (loss) from discontinued operations
119

 
(952
)
Gain from sale of assets and debt settlement, net of tax (CTA included)
3,939

 
—

Net income (loss) from discontinued operations, net of tax
$
4,058

 
$
(952
)

Assets and liabilities of discontinued operations of ECD included in the condensed consolidated balance sheets are summarized as follows at December 31, 2012 and June 30, 2012 (in thousands):
 
December 31,
 
June 30,
 
2012
 
2012
Assets
 
 
 
Accounts receivable
$
—

 
$
1,555

Inventory
—

 
2,348

Other assets
—

 
110

Total current assets
—

 
4,013

Furniture and fixture
—

 
323

Non-current accounts receivable
—

 
69

Goodwill
—

 
93

Intangible assets
—

 
627

Total non-current assets
—

 
1,112

Total Assets
—

 
5,125

Liabilities
 
 
 
Accounts payable
—

 
691

Accrued expenses
—

 
589

Total liabilities
—

 
1,280

Net assets of discontinued operations
$
—

 
$
3,845



ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Forward Looking Statements

Certain statements contained in, or incorporated by reference in, this report are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which provide current expectations or forecasts of future events. Such statements can be identified by the use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “project,” “should,” “will,” and similar words or expressions. The Company's forward-looking statements include certain information relating to general business strategy, growth strategies, financial results, liquidity, discontinued operations, product development, the introduction of new products, the potential markets and uses for the Company's products, the Company's regulatory filings with the FDA, acquisitions, dispositions, the development of joint venture opportunities, intellectual property and patent protection and infringement, the loss of revenue due to the expiration on termination of certain agreements, the effect of competition on the structure of the markets in which the Company competes, increased legal, accounting and Sarbanes-Oxley compliance costs, compliance with Nasdaq continued listing qualifications, defending the Company in litigation matters and the Company's cost saving initiatives. The reader must carefully consider forward-looking statements and understand that such statements involve a variety of risks and uncertainties, known and unknown, and may be affected by assumptions that fail to materialize as anticipated. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. It is not possible to foresee or identify all factors affecting the Company's forward-looking

14

statements, and the reader therefore should not consider the list of such factors contained in its periodic report on Form 10-K for the year ended June 30, 2012 and this Form 10-Q quarterly report to be an exhaustive statement of all risks, uncertainties or potentially inaccurate assumptions.

Executive Overview—Six-Months Ended December 31, 2012 and 2011.

The following highlights are discussed in further detail within this Form 10-Q. The reader is encouraged to read this
Form 10-Q in its entirety to gain a more complete understanding of factors impacting Company performance and financial
condition.
• Consolidated product revenue from continuing operations increased approximately $318,000 or 5.7%, to $5,910,000 during the six-months ended December 31, 2012 as compared to same period of the last fiscal year. The increase in revenue is attributed to an increase in Sonomed’s ultrasound products, EMI’s digital imaging cameras and AXIS image management systems offset by slight a decrease in Trek products.

• Consolidated cost of goods sold from continuing operations totaled approximately $2,972,000, or 50.3%, of product revenue from continuing operations, for the six months ended December 31, 2012, as compared to $2,686,000, or 48.0%, of product revenue from continuing operations, for the same period of the prior fiscal year. The increase of 2.3% in cost of goods sold as a percentage of revenue is due mainly to the product mix sold during the current period.

• Total operating expenses increased approximately $81,000 or 2.4% during the six-month period ended December 31, 2012 as compared to the same period of prior fiscal year. This was due to a $100,000 or 23.3% in research and development expenses offset by decreased marketing, general and administrative expenses of $20,000 or 0.7%.

Company Overview

The following discussion should be read in conjunction with interim condensed consolidated financial statements and
the notes thereto, which are set forth in Item 1 of this report.

The Company operates in the healthcare market specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the areas of ophthalmology, diabetes and hematology. The Company and its products are subject to regulation and inspection by the FDA. The FDA requires extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing. The Company's Internet address is www.escalonmed.com.
Critical Accounting Policies
The preparation of financial statements requires management to make estimates and assumptions that impact amounts reported therein. The most significant of those involve the application of FASB-issued authoritative guidance concerning Revenue Recognition, Goodwill and Other Intangible Assets, discussed further in the notes to consolidated financial statements included in the Form 10-K for the year ended June 30, 2012. The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America, and, as such, include amounts based on informed estimates and judgments of management. For example, estimates are used in determining valuation allowances for deferred income taxes, uncollectible receivables, obsolete inventory, sales returns and rebates, warranty liabilities and purchased intangible assets. Actual results achieved in the future could differ from current estimates. The Company used what it believes are reasonable assumptions and, where applicable, established valuation techniques in making its estimates.
Revenue Recognition
The Company recognizes revenue from the sale of its products at the time of shipment, when title and risk of loss transfer. The Company provides products to its distributors at agreed wholesale prices and to the balance of its customers at set retail prices. Distributors can receive discounts for accepting high volume shipments. The discounts are reflected immediately in the net invoice price, which is the basis for revenue recognition. No further material discounts are given.
 
The Company's considerations for recognizing revenue upon shipment of product to a distributor are based on the following:
 
 
 
Persuasive evidence that an arrangement (purchase order and sales invoice) exists between a willing buyer (distributor) and the Company that outlines the terms of the sale (company information, quantity of goods, purchase price and payment terms). The buyer (distributor) does not have a right of return.
 

15

 
 
Shipping terms are ex-factory shipping point. At this point the buyer (distributor) takes title to the goods and is responsible for all risks and rewards of ownership, including insuring the goods as necessary.
 
 
 
The Company's price to the buyer (distributor) is fixed and determinable as specifically outlined on the sales invoice. The sales arrangement does not have customer cancellation or termination clauses.
 
 
 
The buyer (distributor) places a purchase order with the Company; the terms of the sale are cash, COD or credit. Customer credit is determined based on the Company's policies and procedures related to the buyer's (distributor's) creditworthiness. Based on this determination, the Company believes that collectibility is reasonably assured.
The Company assesses collectibility based on creditworthiness of the customer and past transaction history. The Company performs ongoing credit evaluations of its customers and does not require collateral from its customers. For many of the Company's international customers, the Company requires an irrevocable letter of credit to be issued by the customer before the purchase order is accepted.
Valuation of Intangible Assets
The Company annually evaluates for impairment its intangible assets and goodwill in accordance with SFAS 142, “Goodwill and Other Intangible Assets,” or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. These intangible assets include goodwill, trademarks and trade names. Recoverability of these assets is measured by comparison of their carrying amounts to future discounted cash flows the assets are expected to generate. If identifiable intangibles are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the assets exceeds its fair market value. The Company does not amortize intangible assets with indefinite useful lives, rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. The Company performs its intangible asset impairment tests on or about June 30, of each year. Any such impairment charge could be significant and could have a material adverse impact on the Company's financial statements if and when an impairment charge is recorded.
Income/(Loss) Per Share
The Company computes net income/(loss) per share under the provisions of FASB issued authoritative guidance.
Under the provisions of FASB issued authoritative guidance, basic and diluted net income/(loss) per share is computed by dividing the net income/(loss) for the period by the weighted average number of shares of common stock outstanding during the period. The calculation of diluted net income/(loss) per share excludes potential common shares if the impact is anti-dilutive. Basic earnings per share are computed by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share are determined in the same manner as basic earnings per share, except that the number of shares is increased by assuming exercise of dilutive stock options and warrants using the treasury stock method.

Taxes
Estimates of taxable income of the various legal entities and jurisdictions are used in the tax rate calculation. Management uses judgment in estimating what the Company's income tax will be for the year. Since judgment is involved, there is a risk that the tax rate may significantly increase or decrease in any period.
In determining income/(loss) for financial statement purposes, management must make certain estimates and judgments. These estimates and judgments occur in the calculation of certain tax liabilities and in the determination of the recoverability of certain deferred tax assets, which arise from temporary differences between the tax and financial statement recognition of revenue and expense. FASB issued authoritative guidance concerning accounting for income taxes also requires that the deferred tax assets be reduced by a valuation allowance, if based on the available evidence, it is more likely that not that all or some portion of the recorded deferred tax assets will not be realized in future periods.
In evaluating the Company's ability to recover the Company's deferred tax assets, management considers all available positive and negative evidence including the Company's past operating results, the existence of cumulative losses and near-term forecasts of future taxable income that is consistent with the plans and estimates management is using to manage the underlying businesses.

16

Through December, 31, 2012, the Company has recorded a valuation allowance against the Company's net operating losses for all of the deferred tax assets due to uncertainty of their realization as a result of the Company's earnings history, the number of years the Company's net operating losses and tax credits can be carried forward, the existence of taxable temporary differences and near-term earnings expectations. The amount of the valuation allowance could decrease if facts and circumstances change that materially increase taxable income prior to the expiration of the loss carryforwards. Any reduction would reduce (increase) the income tax expense (benefit) in the period such determination is made by the Company.
The Company anticipates having sufficient net operating loss carry-forwards to offset the net gain on the sale of Drew of $4,019,000, however, due to alternative minimum taxes, the Company has recorded a liability of $80,000 for accrued taxes which is included in the gain on discontinued operations.
The Company has adopted FASB issued guidance related to accounting for uncertainty in income taxes, which provides a comprehensive model for the recognition, measurement, and disclosure in financial statements of uncertain income tax positions that a company has taken or expects to take on a tax return. Under the FASB guidance a company can recognize the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit can be recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Additionally, companies are required to accrue interest and related penalties, if applicable, on all tax exposures for which reserves have been established consistent with jurisdictional tax laws. The Company has elected to recognize interest expense and penalties, if any, related to uncertain tax positions as a component of its provision for income taxes.
Stock-Based Compensation
Stock-based compensation expense for all stock-based compensation awards granted after July 1, 2006 is based on the grant-date fair value estimate in accordance with the provisions of the FASB issued guidance. The Company recognizes these compensation costs on a straight-line basis over the requisite service period of the award.
Valuations are based on highly subjective assumptions about the future, including stock price volatility and exercise patterns. The fair value of share-based payment awards was estimated using the Black-Scholes option pricing model. Expected volatilities are based on the historical volatility of the Company's stock. The Company uses historical data to estimate option exercise and employee terminations. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant.
Results of Operations
Three-Months Ended December 31, 2012 and 2011
The following table shows consolidated product revenue by business segment, as well as identifying trends in business segment product revenues for the three-month and six-month periods ended December 31, 2012 and 2011.
Table amounts are in thousands:
 
Three Months Ended December 31,
 
Six Months Ended December 31,
 
2012
 
2011
 
% Change
 
2012
 
2011
 
% Change
Product Revenue:
 
 
 
 
 
 
 
 
 
 
 
Sonomed-Escalon
$
3,641

 
$
3,186

 
14.3
%
 
$
5,910

 
$
5,593

 
5.7
%
Total
$
3,641

 
$
3,186

 
14.3
%
 
$
5,910

 
$
5,593

 
5.7
%
Consolidated product revenue from continuing operations increased approximately $455,000 or 14.3% to $3,641,000 during the three months ended December 31, 2012 as compared to same period of the last fiscal year. The increase in revenue is attributed to an increase in Sonomed’s ultrasound products, EMI’s digital imaging cameras and AXIS image management systems offset by a decrease in Trek products.
Consolidated product revenue from continuing operations increased approximately $317,000 or 5.7%, to $5,910,000 during the six months ended December 31, 2012 as compared to same period of the last fiscal year. The increase in revenue is attributed to an increase in Sonomed’s ultrasound products and EMI’s digital imaging cameras and AXIS image management systems offset by slight a decrease in Trek products.
The following table presents consolidated cost of goods sold by reportable business segment and as a percentage of related segment product revenues for the three months and six months ended December 31, 2012 and 2011. Table amounts are in thousands:
 

17

 
Three Months Ended December 31,
 
Six Months Ended December 31,
 
2012
 
%
 
2011
 
%
 
2012
 
%
 
2011
 
%
Cost of Goods Sold:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sonomed-Escalon
$
1,776

 
48.8
%
 
$
1,462

 
45.9
%
 
$
2,972

 
50.3
%
 
$
2,686

 
48.0
%
Total
$
1,776

 
48.8
%
 
$
1,462

 
45.9
%
 
$
2,972

 
50.3
%
 
$
2,686

 
48.0
%

Consolidated cost of goods sold from continuing operations totaled approximately $1,776,000 , or 48.8% of product revenue from continuing operations, for the three months ended December 31, 2012, as compared to $1,462,000, or 45.9% of product revenue from continuing operations, for the same period of the prior fiscal year. The increase of 2.9% in cost of goods sold as a percentage of revenue is due mainly to the product mix sold during the current period.

Consolidated cost of goods sold from continuing operations totaled approximately $2,972,000, or 50.3%, of product revenue from continuing operations, for the six months ended December 31, 2012, as compared to $2,686,000, or 48.0%, of product revenue from continuing operations, for the same period of the prior fiscal year. The increase of 2.3% in cost of goods sold as a percentage of revenue is due mainly to the product mix sold during the current period.

The following table presents consolidated marketing, general and administrative expenses as well as identifying trends in business segment marketing, general and administrative expenses for the three months and six months ended December 31, 2012 and 2011. Table amounts are in thousands:
 
 
Three Months Ended December 31,
 
Six Months Ended December 31,
 
2012
 
2011
 
% Change 
 
2012
 
2011
 
% Change 
Marketing, General and Administrative:
 
 
 
 
 
 
 
 
 
 
 
Sonomed-Escalon
$
790

 
$
820

 
(3.7
)%
 
$
1,542

 
$
1,505

 
2.5
 %
Corporate
699

 
714

 
(2.1
)%
 
1,353

 
1,410

 
(4.0
)%
Total
$
1,489

 
$
1,534

 
(3.0
)%
 
$
2,895

 
$
2,915

 
(0.7
)%

Consolidated marketing, general and administrative expenses from continuing operations decreased $45,000, or 3.0%, to $1,489,000 during the three months ended December 31, 2012, as compared to the same period of the prior fiscal year.
Marketing, general and administrative expenses in the Sonomed-Escalon business segment decreased $30,000, or 3.7%, to $790,000 during the three-month period ended December 31, 2012 as compared to the same period last fiscal year. The decrease is due to decreased legal expense and bad debts expenses.
Marketing, general and administrative expenses in the Corporate business segment decreased $15,000, or 2.1% to $699,000 during the three-month period ended December 31, 2012 as compared to the same period last fiscal year. The decrease is due to decreased expense in payroll and consulting offset by increased legal expenses and general insurance expenses.
Consolidated marketing, general and administrative expenses from continuing operations decreased $20,000, or 0.7%, to $2,895,000 during the six-month ended December 31, 2012, as compared to the same period of the prior fiscal year.
Marketing, general and administrative expenses in the Sonomed-Escalon business segment increased $37,000, or 2.5%, to $1,542,000 during the six-month period ended December 31, 2012 as compared to the same period last fiscal year. The increase is due to an increase in sales people and related sales, marketing and advertising expenses.
Marketing, general and administrative expenses in the Corporate business segment decreased $57,000, or 4% to $1,353,000 during the six-month period ended December 31, 2102, as compared to the same period last fiscal year. The decrease is due to decreased expense in payroll and consulting offset by increased legal expenses and general insurance expenses.
The following table presents consolidated research and development expenses from continuing operations by reportable business segment and as a percentage of related segment product revenues for the three-months and six-months ended December 31, 2012 and 2011. Table amounts are in thousands:
 

18

 
Three Months Ended December 31,
 
Six Months Ended December 31,
 
2012
 
2011
 
% Change  
 
2012
 
2011
 
% Change  
Research and Development:
 
 
 
 
 
 
 
 
 
 
 
Sonomed Escalon
$
266

 
$
211

 
26.1
%
 
$
530

 
$
430

 
23.3
%
Total
$
266

 
$
211

 
26.1
%
 
$
530

 
$
430

 
23.3
%
Consolidated research and development expenses from continuing operations increased $55,000, or 26.1% of product revenue, to $266,000 during the three-month period ended December 31, 2012, as compared to the same period of the prior fiscal year. Research and development expenses were primarily expenses associated with the planned introduction of new or enhanced products in the Sonomed-Escalon business units. The increase is related to increased engineering staff and related expenses.
Consolidated research and development expenses from continuing operations increased $100,000, or 23.3% of product revenue, to $530,000 during the six-months period ended December 31, 2012, as compared to the same period of the prior fiscal year. Research and development expenses were primarily expenses associated with the planned introduction of new or enhanced products in the Sonomed-Escalon business units. The increase is related to increased engineering staff and related expenses.

For the three-month period ended December 31, 2012 and 2011, the Company had net income and net loss from discontinued operations of $3,867,000 and $3,426,000, respectively. The current year amount for income from discontinued operations is related to the income from discontinued operations of the ECD segment of $72,000 and $3,939,000 from the sale of Drew's net assets and gain on debt extinguishment net of taxes of $80,000. The prior year amount for loss from discontinued operations includes a loss from discontinued operations of BHH of $2,463,000 and loss from discontinued operations of the ECD segment of $963,000.

For the six-month period ended December 31, 2012 and 2011 the Company had net income and net loss from discontinued operations of $4,058,000 and $3,717,000, respectively. The current year amount for income from discontinued operations is related to the income from discontinued operations of the ECD segment of $119,000 and $3,939,000 from the sale of Drew's net assets and gain on debt extinguishment net of taxes of $80,000. The prior year amount for loss from discontinued operations includes a loss from discontinued operations of BHH of $2,765,000 and loss from discontinued operations of the ECD segment of $952,000.
The Company recognized a gain of $4,000 and $0 related to its investment in Ocular Telehealth Management (“OTM”) during the three-month periods ended December 31, 2012 and 2011, respectively, and recognized a gain of $5,000 and $1,000 for the six-month periods ended December 31, 2012 and 2011, respectively. OTM is an early stage privately held company. OTM began operations during the three-month period ended September 30, 2004. (See note 6 of the notes to the December 31, 2012 condensed consolidated financial statements.)
Interest expense was $0 and $88,000 for the three-month periods ended December 31, 2012 and 2011, respectively, and $93,000 and $171,000 for the six-month periods ended December 31, 2012 and 2011, respectively. The decrease in interest expense during the three-month and six-month periods is due to the settlement of the BHH acquisition debt in October 2012 (see Note 9 of the notes to the December 31, 2012 condensed consolidated financial statements).

Liquidity and Capital Resources
The following table presents overall liquidity and capital resources as of December 31, 2012 and June 30, 2012. Table amounts are in thousands:
 

19

 
December 31, 2012
 
June 30, 2012
Current Ratio:
 
 
 
Current assets
$
7,287

 
$
7,881

Less: Current liabilities
2,249

 
8,063

Working capital
$
5,038

 
$
(182
)
Current ratio
3.2 to 1

 
1.0 to 1

Debt to Total Capital Ratio:
 
 
 
Notes payable and current maturities
$
—

 
$
4,450

Total debt
—

 
4,450

Total equity
4,746

 
645

Total capital
$
4,746

 
$
5,095

Total debt to total capital
—
%
 
87.3
%

Working Capital Position
Working capital increased $5,220,000 as of December 31, 2012, and the current ratio increased to 3.2 to 1 from 1.0 to 1 when compared to June 30, 2012.
Debt to Total Capital Ratio decreased to 0 as of December 31, 2012 from 87.3% when compared to June 30, 2012 as a result of the settlement of BHH debt and payment on the related party note payable during October 2012.
    
On October 3, 2012 the Company sold its Clinical Diagnostics Business to ERBA Diagnostics, Inc. The ECD segment consisted of Drew Scientific, Inc., and its wholly owned subsidiaries JAS and Drew Scientific Limited Co. The sales price was $6,500,000 in cash and the transaction generated a gain on sale of $2,717,000.

On October 18, 2012, the Company and its debt holder reached an agreement whereby the Company paid the balance of the seller-provided financing plus accrued interest related to the purchase of certain assets of Biocode of $4,367,604 with a one-time payment of $2,487,480 resulting in a gain on extinguishment of debt of $1,880,124. The repayment of the debt has reduced the Company's debt related to Biocode to zero. The total gain from the extinguishment of debt and the gain on the sale of assets, offset by the cumulative translation adjustment related to Drew of $578,422 was $4,019,000 before tax.

The total gain brought the Company back into compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing on the NASDAQ Capital Market as set forth in Listing Rule 5550(b).

The Company expects that these transactions will provide the Company with sufficient cash to fund its operations over the next 12 months.


Cash Used In or Provided By Operating Activities
During the six-month periods ended December 31, 2012 and 2011, the Company generated cash outflows from continuing operating activities of $1,105,000 and $266,000, respectively. The net increase in cash used in operating activities of approximately $839,000 for the six-month period ended December 31, 2012, as compared to the same period in the prior fiscal year is due primarily to the following factors:
For the six-month period ended December 31, 2012, the Company had a net income of $3,560,000, which includes net income from discontinued operations of $4,058,000, and experienced net cash in flows from an increase in accounts payable, accrued expenses and other liabilities of $173,000, a decrease in current and long-term assets of $26,000, and non-cash expenditures on depreciation and amortization and compensation expense related to stock options of approximately $7,000 and $26,000, respectively. These cash in-flows were partially offset by an increase in inventory of $278,000 and accounts receivable of $479,000, and other income of $82,000.
For the six-month period ended December 31, 2011, the Company had a net loss of $4,325,000, which includes net loss from discontinued operations of $3,717,000, and experienced net cash in flows from an decrease in accounts receivable of $446,000, increase in accounts payable, accrued expenses and other liabilities of $227,000 and non-cash expenditures on depreciation and amortization and compensation expense related to stock options of approximately $4,000 and $40,000, respectively. These cash

20

in-flows were partially offset by an increase in other current an long-term assets and inventory of $21,000 and $353,000, respectively.
Cash flow from operations also included $88,000 provided by operating activities from discontinued operations and $458,000 used in operating activities from discontinued operations for the six months ended December 31, 2012 and 2011, respectively. These cash inflows and outflows are not expected to recur in future periods.
Cash Flows Used In Investing and Financing Activities
Cash flows from investing activities of $6,491,000 were due to the proceeds from sale of Drew net assets of $6,500,000 and offset by purchase of fixed assets from discontinued operation of $9,000 during the six-month period ended December 31, 2012.
Cash flows used in investing activities of $55,000 were related to purchase of fixed assets during the six-month period ended December 31, 2011, among which $42,000 was related to the purchase of fixed assets in discontinued operations.
Cash flows used in financing activities during the six-month period ended December 31, 2012 were related to the payment for related party note payable of $300,000 and payment for debt settlement of $2,487,000.
Cash flows from financing activities of $144,000 were related to proceeds of $300,000 from a related party note payable offset by the scheduled long-term debt payment of $156,000 during the six-month period ended December 31, 2011.

Debt History
On December 31, 2008, Drew acquired certain assets of Biocode for $5,900,000 (4,200,000 Euros) plus acquisition costs of approximately $300,000. The sales price was payable in cash of approximately $324,000 (approximately 231,000 Euros) and $5,865,000 in debt from Drew. The seller-provided financing is collateralized by certain assets of Biocode. Biocode assets were vertically integrated into the Company’s clinical diagnostics business that includes Drew and JAS.
On April 29, 2011 the Company amended its seller financed debt in connection with the Biocode transaction. Under the terms of the debt refinancing, the Company agreed to pay the balance of the seller provided financing of 3,375,000 Euros by the sum per month in euros having an exchange value of $50,000 United States Dollars as of the date of payment. Interest remained unchanged and will accrue on the outstanding amount of the purchase price at an interest rate of 7% per year on the basis of the actual days elapsed and a 365 day year. The first payment under the amended agreement was paid on May 31, 2011. Upon the 60th month after this Amendment, the Company agreed to pay the balance of the outstanding amount in euros in full in one payment. At the time of the refinancing, the current portion of our long-term debt was reduced from approximately $2,600,000 to $252,000.
On January 12, 2012 BH Holdings, S.A.S.  ("BHH") a wholly owned subsidiary of Drew, initiated the filing of an insolvency declaration with the Tribunal de Commerce de Rennes, France ("Commercial Court").  The Commercial Court on January 18, 2012 opened the liquidation proceedings with continuation of BHH's activity for three months and named an administrator to manage BHH. Because BHH was no longer controlled by Drew it was deconsolidated in the December 31, 2011 quarterly consolidated financial statements and prior period amounts are presented as discontinued operations (see footnote 10 to the Notes to Condensed Consolidated Financial Statements for additional information). This debt was guaranteed by Escalon, and as a result of the insolvency declaration the debt has been transferred to Escalon.
On May 11, 2012, the holder of debt incurred by the Company in connection with its acquisition of BHH informed the Company that it intended to declare the entire amount in default, seek a judgment from a French Court and then enforce the Company’s guarantee for payment. Consequently the Company recorded the entire debt of $4,149,516 as a current liability.
On October 18, 2012, the Company and its debt holder reached an agreement whereby the Company paid off the balance of the seller-provided financing of $4,367,604 with a one-time payment of $2,487,480 resulting in a gain on extinguishment of debt of $1,880,124. The repayment of the debt reduced the Company's debt related to Biocode to zero.
During the six-months period ended December 31, 2012 Richard J. DePiano, Sr., the Company’s Chief Executive Officer, participated in an accounts receivable factoring program that was implemented by the Company. Under the program, Mr. DePiano advanced the Company $300,000 which represented 80% of an amount due from certain Drew customers. The receivables were not eligible to be sold to the Company’s usual factoring agent. Interest on the transaction is 1.25% per month, which is equal to the best price offered by the Company’s usual factoring agent. The transaction excluded fees typically charged by the factoring agent and provided much needed liquidity to the Company. Related party interest expense for the three month periods ended December 31, 2012 and 2011 was $0 and $6,011, respectively. Related party interest expense for the six-month periods ended

21

December 31, 2012 and 2011 was $11,250 and $9,773, respectively. The entire amount due of $332,216 was paid in full on October 5, 2012.

Continuing Operations

The accompany condensed financial statements have been prepared on the going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

Based on the following transactions, the Company expects that these transactions will provide the Company with sufficient cash to fund its operations over the next 12 months.

On October 3, 2012 the Company sold its Clinical Diagnostics Business to ERBA Diagnostics, Inc. The Escalon Clinical Diagnostics Business ("ECD") consisted of Drew Scientific, Inc., and its wholly owned subsidiaries JAS Diagnostics, Inc. ("JAS") and Drew Scientific Limited Co. The sales price was $6,500,000 in cash and the transaction generated a gain on sale of approximately $2,717,000.

On October 18, 2012, the Company and its debt holder reached an agreement whereby the Company paid the balance of the seller-provided financing plus accrued interest related to the purchase of certain assets of Biocode of $4,367,604 with a one-time payment of $2,487,480 resulting in a gain on extinguishment of debt of $1,880,124. The repayment of the debt has reduced the Company's debt related to Biocode to zero. The total gain from the extinguishment of debt and the gain on the sale of assets, offset by the cumulative translation adjustment related to Drew of $578,422 was $4,019,000 before tax.

The total gain brought the Company back into compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing on the NASDAQ Capital Market as set forth in Listing Rule 5550(b).
 
    

Off-Balance Sheet Arrangements and Contractual Obligations

The Company was not a party to any off-balance sheet arrangements during the six-month periods ended December 31, 2012 and 2011.

The following table presents the Company's contractual obligations as of December 31, 2012 (excluding interest):

 
 
 
 
 Less than
 
 
 
3-5
 
More than
 
 
 Total
 
 1 Year
 
 1-3 Years
 
Years
 
 5 Years
 
 
 
 
 
 
 
 
 
 
 
Operating lease agreements
 
$
2,453,050

 
$
609,271

 
$
1,128,897

 
$
714,882

 
$
—

Total
 
$
2,453,050

 
$
609,271

 
$
1,128,897

 
$
714,882

 
$
—



Item 3.    Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk


On October 18, 2012, the Company and its debt holder reached an agreement whereby the Company paid the balance of the seller-provided financing plus accrued interest related to the purchase of certain assets of Biocode of $4,367,604 with a one-time payment of $2,487,480 resulting in a gain on extinguishment of debt of $1,880,124. The repayment of the debt has reduced the Company's debt related to Biocode to zero. In addition, the entire related party debt due of $332,216 including accrued interest of $32,216, was paid in full on October 5, 2012.



Item 4T. Controls and Procedures

(A)    Evaluation of Disclosure Controls and Procedures

22


The Company's management, with the participation of the Company's Chief Executive Officer and Principal Financial and Accounting Officer, have established disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the officers who certify the Company's financial reports and to other members of senior management and the Board of Directors.

Based on their evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2012, the Chief Executive Officer and Principal Financial and Accounting Officer of the Company have concluded that such disclosure controls and procedures are effective to ensure that the information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its Chief Executive Officer and Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosure.

(B)    Internal Control over Financial Reporting

There have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act), during the second fiscal quarter ended December 31, 2012 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Item 1.    Legal Proceedings

See footnote 4 of the notes to the condensed consolidated financial statements for further information regarding the Company's legal proceedings (see footnote 10 for details on the court proceedings related to the insolvency declaration at BHH).

Item 1A. Risk Factors

There are no material changes from the risks previously disclosed in the Company's Annual Report on Form 10-K for the year ended June 30, 2012.


Item 6.    Exhibits
10.1    Stock Purchase Agreement dated as of October 3, 2012 by and among Escalon Medical Corp., Drew Scientific, Inc. and ERBA Diagnostics, Inc. (incorporated by reference to exhibit 2.1 filed with the Company's Form 8-K on October 10, 2012.
31.1    Certificate of Chief Executive Officer under Rule 13a-14(a).
31.2    Certificate of Principal Financial and Accounting Officer under Rule 13a-14(a).
32.1
Certificate of Chief Executive Officer under Section 1350 of Title 18 of the United States Code.
32.2
Certificate of Principal Financial and Accounting Officer under Section 1350 of Title 18 of the United States Code.



















23

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
 
Escalon Medical Corp.
 
 
 
 
(Registrant)
 
 
 
 
 
 
 
Date: February 14, 2013
 
By:
 
/s/ Richard J. DePiano
 
 
 
 
Richard J. DePiano
 
 
 
 
Chairman and Chief Executive Officer
 
 
 
 
 
Date: February14, 2013
 
By:
 
/s/ Robert O’Connor
 
 
 
 
Robert O’Connor
 
 
 
 
Chief Financial Officer



24